U.S. Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
Biomed Res Int. 2013;2013:808391. doi: 10.1155/2013/808391. Epub 2012 Dec 5.
Objective. Healthcare utilization and costs associated with systemic lupus erythematosus (SLE) in a US Medicaid population were examined. Methods. Patients ≥ 18 years old with SLE diagnosis (ICD-9-CM 710.0x) were extracted from a large Medicaid database 2002-2009. Index date was date of the first SLE diagnosis. Patients with and without SLE were matched. All patients had a variable length of followup with a minimum of 12 months. Annualized healthcare utilization and costs associated with SLE and costs of SLE flares were assessed during the followup period. Multivariate regressions were conducted to estimate incremental healthcare utilization and costs associated with SLE. Results. A total of 14,777 SLE patients met the study criteria, and 14,262 were matched to non-SLE patients. SLE patients had significantly higher healthcare utilization per year than their matched controls. The estimated incremental annual cost associated with SLE was $10,984, with the highest increase in inpatient costs (P < 0.001). Cost per flare was $11,716 for severe flares, $562 for moderate flares, and $129 for mild flares. Annual total costs for patients with severe flares were $49,754. Conclusions. SLE patients had significantly higher healthcare resource utilization and costs than non-SLE patients. Patients with severe flares had the highest costs.
研究美国医疗补助计划(Medicaid)人群中系统性红斑狼疮(SLE)的医疗利用和相关成本。
从 2002 年至 2009 年期间的大型 Medicaid 数据库中提取年龄≥18 岁的 SLE 诊断(ICD-9-CM 710.0x)患者。索引日期为首次 SLE 诊断日期。对有和没有 SLE 的患者进行匹配。所有患者的随访时间至少为 12 个月,随访期间评估 SLE 相关的年度医疗利用和成本以及 SLE 发作的成本。采用多元回归估计 SLE 相关的增量医疗利用和成本。
共纳入 14777 例符合研究标准的 SLE 患者,对其中 14262 例患者进行了匹配。SLE 患者每年的医疗利用显著高于匹配对照组。与 SLE 相关的估计增量年度费用为 10984 美元,其中住院费用增加最多(P<0.001)。严重发作的每次发作费用为 11716 美元,中度发作为 562 美元,轻度发作为 129 美元。严重发作患者的年总费用为 49754 美元。
SLE 患者的医疗资源利用和费用明显高于非 SLE 患者。严重发作患者的费用最高。